

Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 420
Montréal, Québec CA H4M 2X6

VIA EDGAR

November 20, 2024

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn: Chris Edwards

Re: **Milestone Pharmaceuticals Inc.**
Registration Statement on Form S-3
File No. 333-283162

Acceleration Request

Requested Date: Friday, November 22, 2024
Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “**Registrant**”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-283162) (the “**Registration Statement**”) to become effective on Friday, November 22, 2024, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff.

The Registrant hereby authorizes each of Ryan S. Sansom and Sarah E. Curry of Cooley LLP to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Sarah E. Curry of Cooley LLP, counsel to the undersigned registrant, at (212) 479-6652.

[Signature Page Follows]

Sincerely,

MILESTONE PHARMACEUTICALS INC.

By: /s/ Joseph Oliveto

Joseph Oliveto
Chief Executive Officer

cc: Amit Hasija, Milestone Pharmaceuticals Inc.
Ryan S. Sansom, Cooley LLP
Sarah E. Curry, Cooley LLP
